ALD-301

N/A

Report date: 2022/07/19 20:00:45

Base Information

Drug NameALD-301
Drug Alias NameALD-301
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Aldehyde Dehydrogenase-Bright (ALDHbr) Cells
Mechanisms of ActionCell replacementsAngiogenesis inducers
TargetsNot applicable
Therapy Area/IndicationsIschemiaPeripheral Vascular DiseasesIntermittent Claudication +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNuo Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesThe University Of Texas Health Science Center At HoustonAldagen Inc
Active IndicationsN/A
Inactive IndicationsIschemiaPeripheral Vascular DiseasesIntermittent Claudication +[4] 

Other Information

ATC CodeN/A
Related LinksN/A